{"id":"W4390590466","doi":"10.1093/oncolo/oyad337","title":"CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Astellas Pharma; Ipsen; Clovis Oncology; Gilead Sciences; Eisai; Daiichi Sankyo Europe; Sanofi; Instituto de Salud Carlos III; Amgen; Pfizer; PharmaMar; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Oncolytics Biotech","keywords":"Medicine; Hazard ratio; Internal medicine; Chemotherapy; Breast cancer; Oncology; Confidence interval; Progression-free survival; Randomized controlled trial; Gastroenterology; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009551173,0.0003106984,0.0009903804,0.0001329209,0.0001873035,0.00002051858,0.0002072036,0.0001230752,0.0000955603],"category_scores_gemma":[0.0006999269,0.0001543152,0.0002953032,0.0008376036,0.002111631,0.000129598,0.0001027106,0.0004154007,0.000002046755],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004556652,"about_ca_system_score_gemma":0.0003698395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001649754,"about_ca_topic_score_gemma":0.0004218357,"domain_scores_codex":[0.9977093,0.0005146427,0.0006929194,0.0004444499,0.0003379456,0.0003007796],"domain_scores_gemma":[0.9963647,0.002631627,0.0003893834,0.000419434,0.0001247254,0.00007020368],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8847249,0.0003728829,0.000028775,0.00003359886,0.000723007,0.00001738214,0.002745296,0.0001101243,0.004771725,0.0001484299,0.0002030945,0.1061208],"study_design_scores_gemma":[0.9785029,0.001850732,0.001930331,0.0006755558,0.00058082,0.0000356835,0.001762339,0.001351258,0.01053651,0.00096189,0.001587034,0.0002249223],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9646773,0.005822018,0.0001248668,0.0194639,0.002449452,0.003920048,0.0004019475,0.0001135104,0.003026948],"genre_scores_gemma":[0.9971221,0.0009329684,0.0002112536,0.0002020744,0.0002905832,0.0003199018,0.00001024102,0.00003668003,0.0008742146],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1058959,"threshold_uncertainty_score":0.7780393,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05329712438884447,"score_gpt":0.4183184199007502,"score_spread":0.3650212955119057,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}